文献速递膀胱癌与上尿路尿路上皮癌

性别差异对肌层浸润性膀胱癌放化疗后肿瘤结局的影响:回顾性多中心队列研究

Effect of Sex Differences on Cancer Outcomes After Chemo-Radiation for Muscle-Invasive Bladder Cancer: A Retrospective Multicenter Cohort Study.
PubMed 文献 · Urology · 2025-06-28

该回顾性多中心队列研究纳入加拿大10个学术中心接受根治性放化疗的肌层浸润性膀胱癌患者,比较男女肿瘤结局。共397例男性和145例女性,中位随访30个月。完全缓解率无差异,但女性3年肿瘤特异性生存率较低(70.4% vs 78.4%),中位总生存期较短(52 vs 81个月)。多变量分析显示性别与肿瘤特异性生存独立相关(HR 1.46,95%CI 0.95-2.24),但与总生存无关。

要点

  • 女性MIBC患者放化疗后3年肿瘤特异性生存率低于男性。
  • 完全缓解率在两性间无显著差异。
  • 性别与CSS独立相关但CI跨1,需进一步验证。

核心结论

  • 接受放化疗的肌层浸润性膀胱癌女性患者肿瘤特异性生存较男性差。

研究设计与样本

  • 回顾性多中心队列研究,纳入加拿大10个学术中心接受根治性放化疗的MIBC患者,共397例男性和145例女性,中位随访30个月。

主要发现

  • 完全缓解率男性72.3%、女性73.1%,无差异。
  • 3年CSS男性78.4%、女性70.4%;中位OS男性81个月、女性52个月。
  • 器官局限性疾病两性累积死亡率相似,非器官局限性疾病女性更高。
  • 多变量分析中性别与CSS独立相关(HR 1.46,95%CI 0.95-2.24),与OS无关。

临床怎么用

  • 临床中应关注女性MIBC患者放化疗后的肿瘤特异性生存差异,并探索分期及治疗反应等因素。

局限性

  • 回顾性设计可能存在混杂,性别与CSS关联的95%CI跨1,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine whether the well demonstrated sex-based differences in bladder cancer management and outcomes are similarly observed for those treated with chemo-radiation for muscle invasive bladder cancer (MIBC). METHODS: This retrospective, multicenter study reports on patients who underwent curative intent radiotherapy, with concurrent chemotherapy, for MIBC across 10 academic centers in Canada. The primary outcome was cancer specific survival (CSS) and secondary outcomes included complete response and overall survival (OS). Survival was estimated using the Kaplan-Meier method. Multivariable regression models were performed to assess an independent association of sex on outcomes. RESULTS: There were 397 males and 145 females who underwent curative intent chemo-radiation for MIBC with a total median follow-up of 30 months. Baseline cancer characteristics and treatment specifics were similar between the sexes, although complete resection was more common in males and hydronephrosis was more common in females. There were no differences in complete response rates between males and females (72.3% vs 73.1%). The 3-year CSS was 78.4% vs 70.4% for males and females respectively and median OS was 81 months vs 52 months. Cumulative incidence of mortality was similar between the sexes with organ-confined disease but higher for females with non-organ-confined disease. In multivariable analysis, sex was independently associated with CSS (HR 1.46, 95% CI 0.95-2.24) but not OS. CONCLUSION: This multicenter study demonstrated worse CSS in females undergoing chemo-radiation. Future investigations should explore potential effects from differences in staging, as well as other biological- and treatment-related factors, including differential responses to chemo-sensitized radiation.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. MacIntyre I, Kool R, Marcq G, et al. Effect of Sex Differences on Cancer Outcomes After Chemo-Radiation for Muscle-Invasive Bladder Cancer: A Retrospective Multicenter Cohort Study. Urology. 2025. PMID: 40588038. doi:10.1016/j.urology.2025.06.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。